Esperion's Multiple Positives, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Seeking Alpha
Summary Esperion has bempedoic acid PDUFA up ahead. Merck's Ebola medicine receives African approval. AstraZeneca slips on estimates miss. Esperion Therapeutics Anticipates Positive News For Two Of Its Drug Candidates Esperion Therapeutics ( ESPR awaiting Epserion and the markets seem positive about the upcoming events as the company has already received the green The positive recommendation from CHMP will be reviewed by the European Commission and the final decision is expected to be out in April 2020. The decision will be an applicable to all 27 European Union member states and will extend to the United Kingdom, Liechtenstein, Norway and Iceland. The company had used the data from the Phase 3 Fixed Dose Combination Tablet LDL-Cholesterol Lowering program for supporting its application. The bempedoic acid/ezetimibe fixed dose combination tablet was found to have significantly reduced LDL-C 38 percent from baseline to week 12 compared with placebo. Esperion is currently in prime posit
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily WithdrawnBusiness Wire
- Maker Of Chemicals For Sharper X-ray Images Is Newest Indian Billionaire [Forbes]Forbes
- QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML [Yahoo! Finance]Yahoo! Finance
- QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AMLBusiness Wire
- Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerBusiness Wire